153 related articles for article (PubMed ID: 25270552)
1. Silencing of the glypican-3 gene affects the biological behavior of human hepatocellular carcinoma cells.
Qi XH; Wu D; Cui HX; Ma N; Su J; Wang YT; Jiang YH
Mol Med Rep; 2014 Dec; 10(6):3177-84. PubMed ID: 25270552
[TBL] [Abstract][Full Text] [Related]
2. Silencing glypican-3 expression induces apoptosis in human hepatocellular carcinoma cells.
Liu S; Li Y; Chen W; Zheng P; Liu T; He W; Zhang J; Zeng X
Biochem Biophys Res Commun; 2012 Mar; 419(4):656-61. PubMed ID: 22382024
[TBL] [Abstract][Full Text] [Related]
3. Glypican-3 promotes epithelial-mesenchymal transition of hepatocellular carcinoma cells through ERK signaling pathway.
Wu Y; Liu H; Weng H; Zhang X; Li P; Fan CL; Li B; Dong PL; Li L; Dooley S; Ding HG
Int J Oncol; 2015 Mar; 46(3):1275-85. PubMed ID: 25572615
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of glypican-3 expression via RNA interference influences the growth and invasive ability of the MHCC97-H human hepatocellular carcinoma cell line.
Ruan J; Liu F; Chen X; Zhao P; Su N; Xie G; Chen J; Zheng D; Luo R
Int J Mol Med; 2011 Oct; 28(4):497-503. PubMed ID: 21617840
[TBL] [Abstract][Full Text] [Related]
5. Long noncoding RNA glypican 3 (GPC3) antisense transcript 1 promotes hepatocellular carcinoma progression via epigenetically activating GPC3.
Zhu XT; Yuan JH; Zhu TT; Li YY; Cheng XY
FEBS J; 2016 Oct; 283(20):3739-3754. PubMed ID: 27573079
[TBL] [Abstract][Full Text] [Related]
6. Reduced nucleic ZHX2 involves in oncogenic activation of glypican 3 in human hepatocellular carcinoma.
Luan F; Liu P; Ma H; Yue X; Liu J; Gao L; Liang X; Ma C
Int J Biochem Cell Biol; 2014 Oct; 55():129-35. PubMed ID: 25195714
[TBL] [Abstract][Full Text] [Related]
7. Glypican-3 induces a mesenchymal to epithelial transition in human breast cancer cells.
Castillo LF; Tascón R; Lago Huvelle MR; Novack G; Llorens MC; Dos Santos AF; Shortrede J; Cabanillas AM; Bal de Kier Joffé E; Labriola L; Peters MG
Oncotarget; 2016 Sep; 7(37):60133-60154. PubMed ID: 27507057
[TBL] [Abstract][Full Text] [Related]
8. The significance of glypican-3 expression profiling in the tumor cellular origin theoretical system for hepatocellular carcinoma progression.
Xue R; Feng J; Meng Q; Lv F; Zhu Y; Yu H; Zhang S; Song C; Sun L; Yue Z; Feng S; Che R; Xiang Q; Jing X
J Gastroenterol Hepatol; 2017 Aug; 32(8):1503-1511. PubMed ID: 28087980
[TBL] [Abstract][Full Text] [Related]
9. Knockdown of GPC3 inhibits the proliferation of Huh7 hepatocellular carcinoma cells through down-regulation of YAP.
Miao HL; Pan ZJ; Lei CJ; Wen JY; Li MY; Liu ZK; Qiu ZD; Lin MZ; Chen NP; Chen M
J Cell Biochem; 2013 Mar; 114(3):625-31. PubMed ID: 23060277
[TBL] [Abstract][Full Text] [Related]
10. Long non-coding RNA FENDRR inhibits proliferation and invasion of hepatocellular carcinoma by down-regulating glypican-3 expression.
Wang B; Xian J; Zang J; Xiao L; Li Y; Sha M; Shen M
Biochem Biophys Res Commun; 2019 Jan; 509(1):143-147. PubMed ID: 30573358
[TBL] [Abstract][Full Text] [Related]
11. Suppression of glypican 3 inhibits growth of hepatocellular carcinoma cells through up-regulation of TGF-β2.
Sun CK; Chua MS; He J; So SK
Neoplasia; 2011 Aug; 13(8):735-47. PubMed ID: 21847365
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of GPC3 inhibits hepatocellular carcinoma cell proliferation and invasion through induction of apoptosis.
Pan Z; Chen C; Long H; Lei C; Tang G; Li L; Feng J; Chen F
Mol Med Rep; 2013 Mar; 7(3):969-74. PubMed ID: 23338845
[TBL] [Abstract][Full Text] [Related]
13. Role of Glypican-3 in the growth, migration and invasion of primary hepatocytes isolated from patients with hepatocellular carcinoma.
Montalbano M; Rastellini C; McGuire JT; Prajapati J; Shirafkan A; Vento R; Cicalese L
Cell Oncol (Dordr); 2018 Apr; 41(2):169-184. PubMed ID: 29204978
[TBL] [Abstract][Full Text] [Related]
14. Expression of glypican 3 enriches hepatocellular carcinoma development-related genes and associates with carcinogenesis in cirrhotic livers.
Liu X; Wang SK; Zhang K; Zhang H; Pan Q; Liu Z; Pan H; Xue L; Yen Y; Chu PG
Carcinogenesis; 2015 Feb; 36(2):232-42. PubMed ID: 25542894
[TBL] [Abstract][Full Text] [Related]
15. Oncogenic activation of glypican-3 by c-Myc in human hepatocellular carcinoma.
Li L; Jin R; Zhang X; Lv F; Liu L; Liu D; Liu K; Li N; Chen D
Hepatology; 2012 Oct; 56(4):1380-90. PubMed ID: 22706665
[TBL] [Abstract][Full Text] [Related]
16. New tumor suppressor microRNAs target glypican-3 in human liver cancer.
Cartier F; Indersie E; Lesjean S; Charpentier J; Hooks KB; Ghousein A; Desplat A; Dugot-Senant N; Trézéguet V; Sagliocco F; Hagedorn M; Grosset CF
Oncotarget; 2017 Jun; 8(25):41211-41226. PubMed ID: 28476031
[TBL] [Abstract][Full Text] [Related]
17. Human Monoclonal Antibody Targeting the Heparan Sulfate Chains of Glypican-3 Inhibits HGF-Mediated Migration and Motility of Hepatocellular Carcinoma Cells.
Gao W; Kim H; Ho M
PLoS One; 2015; 10(9):e0137664. PubMed ID: 26332121
[TBL] [Abstract][Full Text] [Related]
18. Both glypican-3/Wnt/β-catenin signaling pathway and autophagy contributed to the inhibitory effect of curcumin on hepatocellular carcinoma.
Hu P; Ke C; Guo X; Ren P; Tong Y; Luo S; He Y; Wei Z; Cheng B; Li R; Luo J; Meng Z
Dig Liver Dis; 2019 Jan; 51(1):120-126. PubMed ID: 30001951
[TBL] [Abstract][Full Text] [Related]
19. Role of Glycanation and Convertase Maturation of Soluble Glypican-3 in Inhibiting Proliferation of Hepatocellular Carcinoma Cells.
Saad A; Liet B; Joucla G; Santarelli X; Charpentier J; Claverol S; Grosset CF; Trézéguet V
Biochemistry; 2018 Feb; 57(7):1201-1211. PubMed ID: 29345911
[TBL] [Abstract][Full Text] [Related]
20. Development of T cells redirected to glypican-3 for the treatment of hepatocellular carcinoma.
Gao H; Li K; Tu H; Pan X; Jiang H; Shi B; Kong J; Wang H; Yang S; Gu J; Li Z
Clin Cancer Res; 2014 Dec; 20(24):6418-28. PubMed ID: 25320357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
